Rapport Therapeutics (RAPP) Income towards Parent Company (2023 - 2026)

Rapport Therapeutics (RAPP) has reported Income towards Parent Company for 4 consecutive years, with -$143.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Income towards Parent Company rose 98.82% year-over-year to -$143.7 million; the TTM figure through Mar 2026 stood at -$474.1 million (up 96.13% YoY), while the FY2025 annual figure was -$225.3 million, down 187.74% from the prior year.
• Income towards Parent Company advanced to -$143.7 million in Q1 2026 per RAPP's latest filing, from -$147.6 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$6.4 million in Q2 2023 and bottomed at -$12.2 billion in Q1 2025.
• Historically, Income towards Parent Company has averaged -$1.1 billion across 4 years, with a median of -$19.1 million in 2024.
• Annual changes were most pronounced in 2025 — Income towards Parent Company sank 79809.42% — and 2026, when it surged 98.82%.
• Rapport Therapeutics' Income towards Parent Company stood at -$13.5 million in 2023, then sank by 47.79% to -$20.0 million in 2024, then plunged by 638.75% to -$147.6 million in 2025, then rose by 2.65% to -$143.7 million in 2026.
• Business Quant data shows RAPP's Income towards Parent Company at -$143.7 million in Q1 2026, -$147.6 million in Q4 2025, and -$139.3 million in Q3 2025.